This content is from: Features

Poison pill ruling may weaken French targets

Aventis and Sanofi-Synthelabo are set to merge after a tense three-month standoff. But at what price? Megan Murphy looks at whether a regulatory decision could leave French companies more vulnerable to takeover

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial